| Year |
Citation |
Score |
| 2021 |
Hitt DM, Zwicker JD, Chao CK, Patel SA, Gerdes JM, Bridges RJ, Thompson CM. Inhibition of the Vesicular Glutamate Transporter (VGLUT) with Congo Red Analogs: New Binding Insights. Neurochemical Research. PMID 33398639 DOI: 10.1007/s11064-020-03182-0 |
0.66 |
|
| 2014 |
Carrigan CN, Patel SA, Cox HD, Bolstad ES, Gerdes JM, Smith WE, Bridges RJ, Thompson CM. The development of benzo- and naphtho-fused quinoline-2,4-dicarboxylic acids as vesicular glutamate transporter (VGLUT) inhibitors reveals a possible role for neuroactive steroids. Bioorganic & Medicinal Chemistry Letters. 24: 850-4. PMID 24424130 DOI: 10.1016/J.Bmcl.2013.12.086 |
0.69 |
|
| 2014 |
Newell JL, Keyari CM, McDaniel SW, Diaz PJ, Natale NR, Patel SA, Bridges RJ. Novel di-aryl-substituted isoxazoles act as noncompetitive inhibitors of the system Xc(-) cystine/glutamate exchanger. Neurochemistry International. 73: 132-8. PMID 24333322 DOI: 10.1016/J.Neuint.2013.11.012 |
0.717 |
|
| 2013 |
Matti AA, Mirzaei J, Rudolph J, Smith SA, Newell JL, Patel SA, Braden MR, Bridges RJ, Natale NR. Microwave accelerated synthesis of isoxazole hydrazide inhibitors of the system xc- transporter: Initial homology model. Bioorganic & Medicinal Chemistry Letters. 23: 5931-5. PMID 24042010 DOI: 10.1016/J.Bmcl.2013.08.080 |
0.551 |
|
| 2012 |
Bridges R, Lutgen V, Lobner D, Baker DA. Thinking outside the cleft to understand synaptic activity: contribution of the cystine-glutamate antiporter (System xc-) to normal and pathological glutamatergic signaling. Pharmacological Reviews. 64: 780-802. PMID 22759795 DOI: 10.1124/Pr.110.003889 |
0.553 |
|
| 2012 |
Bridges RJ, Natale NR, Patel SA. System xc⁻ cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS. British Journal of Pharmacology. 165: 20-34. PMID 21564084 DOI: 10.1111/J.1476-5381.2011.01480.X |
0.69 |
|
| 2011 |
Pathmajeyan MS, Patel SA, Carroll JA, Seib T, Striebel JF, Bridges RJ, Chesebro B. Increased excitatory amino acid transport into murine prion protein knockout astrocytes cultured in vitro. Glia. 59: 1684-94. PMID 21766339 DOI: 10.1002/Glia.21215 |
0.738 |
|
| 2011 |
Ahmed SK, Etoga JL, Patel SA, Bridges RJ, Thompson CM. Use of the hydantoin isostere to produce inhibitors showing selectivity toward the vesicular glutamate transporter versus the obligate exchange transporter system x(c)(-). Bioorganic & Medicinal Chemistry Letters. 21: 4358-62. PMID 21669531 DOI: 10.1016/J.Bmcl.2011.05.018 |
0.688 |
|
| 2011 |
Seib TM, Patel SA, Bridges RJ. Regulation of the system x(C)- cystine/glutamate exchanger by intracellular glutathione levels in rat astrocyte primary cultures. Glia. 59: 1387-401. PMID 21590811 DOI: 10.1002/Glia.21176 |
0.722 |
|
| 2010 |
Ye R, Rhoderick JF, Thompson CM, Bridges RJ. Functional expression, purification and high sequence coverage mass spectrometric characterization of human excitatory amino acid transporter EAAT2. Protein Expression and Purification. 74: 49-59. PMID 20399272 DOI: 10.1016/J.Pep.2010.04.006 |
0.578 |
|
| 2010 |
Etoga JL, Ahmed SK, Patel S, Bridges RJ, Thompson CM. Conformationally-restricted amino acid analogues bearing a distal sulfonic acid show selective inhibition of system x(c)(-) over the vesicular glutamate transporter. Bioorganic & Medicinal Chemistry Letters. 20: 2680-3. PMID 20303751 DOI: 10.1016/J.Bmcl.2009.10.020 |
0.686 |
|
| 2010 |
Patel SA, Rajale T, O'Brien E, Burkhart DJ, Nelson JK, Twamley B, Blumenfeld A, Szabon-Watola MI, Gerdes JM, Bridges RJ, Natale NR. Isoxazole analogues bind the system xc- transporter: structure-activity relationship and pharmacophore model. Bioorganic & Medicinal Chemistry. 18: 202-13. PMID 19932968 DOI: 10.1016/J.Bmc.2009.11.001 |
0.619 |
|
| 2010 |
Balázs R, Bridges RJ, Cotman CW. Glutamate and Glutamate Receptors in Neurological Diseases Excitatory Amino Acid Transmission in Health and Disease. 1-46. DOI: 10.1093/acprof:oso/9780195150025.003.0012 |
0.352 |
|
| 2010 |
Balázs R, Bridges RJ, Cotman CW. Trafficking of Glutamate Receptors Excitatory Amino Acid Transmission in Health and Disease. 1-22. DOI: 10.1093/acprof:oso/9780195150025.003.0010 |
0.303 |
|
| 2010 |
Balázs R, Bridges RJ, Cotman CW. Metabotropic Glutamate Receptors Excitatory Amino Acid Transmission in Health and Disease. 1-64. DOI: 10.1093/acprof:oso/9780195150025.003.0007 |
0.302 |
|
| 2010 |
Bridges RJ, Kavanaugh MP, Chamberlin AR. ChemInform Abstract: A Pharmacological Review of Competitive Inhibitors and Substrates of High-Affinity, Sodium-Dependent Glutamate Transport in the Central Nervous System Cheminform. 30: no-no. DOI: 10.1002/chin.199929281 |
0.441 |
|
| 2009 |
Bridges RJ, Patel SA. Pharmacology of glutamate transport in the cns: Substrates and inhibitors of excitatory amino acid transporters (EAATs) and the glutamate/cystine exchanger system x c- Topics in Medicinal Chemistry. 4: 187-222. DOI: 10.1007/7355_2008_026 |
0.747 |
|
| 2008 |
Natale NR, Szabon-Watola MI, Twamley B, Bridges RJ, Patel S, Rajale T. Ethyl 4-{1-[(2,4-dinitro-phen-yl)hydrazono]eth-yl}-5-(2-naphthyl-methoxy-meth-yl)isoxazole-3-carboxyl-ate. Acta Crystallographica. Section E, Structure Reports Online. 65: o144-5. PMID 21581603 DOI: 10.1107/S1600536808041901 |
0.494 |
|
| 2008 |
Mavencamp TL, Rhoderick JF, Bridges RJ, Esslinger CS. Synthesis and preliminary pharmacological evaluation of novel derivatives of L-beta-threo-benzylaspartate as inhibitors of the neuronal glutamate transporter EAAT3. Bioorganic & Medicinal Chemistry. 16: 7740-8. PMID 18650095 DOI: 10.1016/J.Bmc.2008.07.001 |
0.463 |
|
| 2005 |
Esslinger CS, Agarwal S, Gerdes J, Wilson PA, Davis ES, Awes AN, O'Brien E, Mavencamp T, Koch HP, Poulsen DJ, Rhoderick JF, Chamberlin AR, Kavanaugh MP, Bridges RJ. The substituted aspartate analogue L-beta-threo-benzyl-aspartate preferentially inhibits the neuronal excitatory amino acid transporter EAAT3. Neuropharmacology. 49: 850-61. PMID 16183084 DOI: 10.1016/J.Neuropharm.2005.08.009 |
0.662 |
|
| 2005 |
Bridges RJ, Esslinger CS. The excitatory amino acid transporters: pharmacological insights on substrate and inhibitor specificity of the EAAT subtypes. Pharmacology & Therapeutics. 107: 271-85. PMID 16112332 DOI: 10.1016/j.pharmthera.2005.01.002 |
0.566 |
|
| 2005 |
Thompson CM, Davis E, Carrigan CN, Cox HD, Bridges RJ, Gerdes JM. Inhibitor of the glutamate vesicular transporter (VGLUT). Current Medicinal Chemistry. 12: 2041-56. PMID 16101493 DOI: 10.2174/0929867054637635 |
0.521 |
|
| 2004 |
Warren BA, Patel SA, Nunn PB, Bridges RJ. The Lathyrus excitotoxin beta-N-oxalyl-L-alpha,beta-diaminopropionic acid is a substrate of the L-cystine/L-glutamate exchanger system xc-. Toxicology and Applied Pharmacology. 200: 83-92. PMID 15476861 DOI: 10.1016/J.Taap.2004.04.001 |
0.706 |
|
| 2004 |
Patel SA, Warren BA, Rhoderick JF, Bridges RJ. Differentiation of substrate and non-substrate inhibitors of transport system xc(-): an obligate exchanger of L-glutamate and L-cystine. Neuropharmacology. 46: 273-84. PMID 14680765 DOI: 10.1016/J.Neuropharm.2003.08.006 |
0.759 |
|
| 2002 |
Denton T, Seib T, Bridges R, Thompson C. Synthesis and preliminary evaluation of trans-3,4-conformationally-restricted glutamate and pyroglutamate analogues as novel EAAT2 inhibitors. Bioorganic & Medicinal Chemistry Letters. 12: 3209-13. PMID 12372536 DOI: 10.1016/S0960-894X(02)00520-6 |
0.757 |
|
| 2002 |
Esslinger CS, Titus J, Koch HP, Bridges RJ, Chamberlin AR. Methylation of l-trans-2,4-pyrrolidine dicarboxylate converts the glutamate transport inhibitor from a substrate to a non-substrate inhibitor Bioorganic and Medicinal Chemistry. 10: 3509-3515. PMID 12213465 DOI: 10.1016/S0968-0896(02)00250-X |
0.518 |
|
| 2002 |
Carrigan CN, Bartlett RD, Esslinger CS, Cybulski KA, Tongcharoensirikul P, Bridges RJ, Thompson CM. Synthesis and in vitro pharmacology of substituted quinoline-2,4-dicarboxylic acids as inhibitors of vesicular glutamate transport. Journal of Medicinal Chemistry. 45: 2260-76. PMID 12014964 DOI: 10.1021/Jm010261Z |
0.452 |
|
| 1998 |
Bartlett RD, Esslinger CS, Thompson CM, Bridges RJ. Substituted quinolines as inhibitors of L-glutamate transport into synaptic vesicles. Neuropharmacology. 37: 839-46. PMID 9776380 DOI: 10.1016/S0028-3908(98)00080-X |
0.553 |
|
| 1997 |
Willis CL, Dauenhauer DL, Humphrey JM, Chamberlin AR, Buller AL, Monaghan DT, Bridges RJ. Methylation of the NMDA receptor agonist L-trans-2,3-pyrrolidine-dicarboxylate: enhanced excitotoxic potency and selectivity. Toxicology and Applied Pharmacology. 144: 45-55. PMID 9169068 DOI: 10.1006/Taap.1997.8112 |
0.341 |
|
| 1996 |
Willis CL, Humphrey JM, Koch HP, Hart JA, Blakely T, Ralston L, Baker CA, Shim S, Kadri M, Chamberlin AR, Bridges RJ. L-trans-2,3-pyrrolidine dicarboxylate: characterization of a novel excitotoxin. Neuropharmacology. 35: 531-9. PMID 8887961 DOI: 10.1016/0028-3908(96)84623-5 |
0.434 |
|
| 1996 |
Sonnenberg JD, Koch HP, Willis CL, Bradbury P, Dauenhauer D, Bridges RJ, Chamberlin AR. The role of the C-4 side chain of kainate and dihydrokainate in EAA receptor and transporter selectivity Bioorganic and Medicinal Chemistry Letters. 6: 1607-1612. DOI: 10.1016/S0960-894X(96)00284-3 |
0.4 |
|
| 1993 |
Miller S, Nunn PB, Bridges RJ. Induction of astrocyte glutamine synthetase activity by the Lathyrus toxin beta-N-oxalyl-L-alpha,beta-diaminopropionic acid (beta-L-ODAP). Glia. 7: 329-36. PMID 7686536 DOI: 10.1002/glia.440070408 |
0.376 |
|
| 1993 |
Bridges RJ, Lovering FE, Humphrey JM, Stanley MS, Blakely TN, Cristofaro MF, Chamberlin AR. Conformationally restricted inhibitors of the high affinity L-glutamate transporter Bioorganic and Medicinal Chemistry Letters. 3: 115-121. DOI: 10.1016/S0960-894X(00)80103-1 |
0.535 |
|
| 1992 |
Bridges RJ, Hatalski C, Shim SN, Nunn PB. Gliotoxic properties of the Lathyrus excitotoxin beta-N-oxalyl-L-alpha,beta-diaminopropionic acid (beta-L-ODAP). Brain Research. 561: 262-8. PMID 1802342 DOI: 10.1016/0006-8993(91)91602-W |
0.309 |
|
| 1992 |
Bridges RJ, Hatalski CG, Shim SN, Cummings BJ, Vijayan V, Kundi A, Cotman CW. Gliotoxic actions of excitatory amino acids. Neuropharmacology. 31: 899-907. PMID 1436396 DOI: 10.1016/0028-3908(92)90128-C |
0.46 |
|
| 1991 |
Anderson KJ, Bridges RJ, Cotman CW. Increased density of excitatory amino acid transport sites in the hippocampal formation following an entorhinal lesion Brain Research. 562: 285-290. PMID 1685344 DOI: 10.1016/0006-8993(91)90633-7 |
0.489 |
|
| 1990 |
Anderson KJ, Monaghan DT, Bridges RJ, Tavoularis AL, Cotman CW. Autoradiographic characterization of putative excitatory amino acid transport sites Neuroscience. 38: 311-322. PMID 1979852 DOI: 10.1016/0306-4522(90)90030-8 |
0.439 |
|
| 1987 |
Bridges RJ, Kesslak JP, Nieto-Sampedro M, Broderick JT, Yu J, Cotman CW. A L-[3H]glutamate binding site on glia: an autoradiographic study on implanted astrocytes. Brain Research. 415: 163-8. PMID 2887242 DOI: 10.1016/0006-8993(87)90281-2 |
0.453 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2010 |
Balázs R, Bridges RJ, Cotman CW. Delta Glutamate Receptors Excitatory Amino Acid Transmission in Health and Disease. 1-6. DOI: 10.1093/acprof:oso/9780195150025.003.0006 |
0.296 |
|
| 2010 |
Balázs R, Bridges RJ, Cotman CW. Ionotropic Glutamate Receptors: General Characteristics Excitatory Amino Acid Transmission in Health and Disease. 1-23. DOI: 10.1093/acprof:oso/9780195150025.003.0002 |
0.294 |
|
| 1991 |
Gardner VO, Caiozzo VJ, Munden SK, Bridges RJ. Excitotoxins can produce protein degradation in the spinal cord. Spine. 15: 858-63. PMID 1979692 DOI: 10.1097/00007632-199009000-00004 |
0.283 |
|
| 1986 |
Bridges RJ, Hearn TJ, Monaghan DT, Cotman CW. A comparison of 2-amino-4-phosphonobutyric acid (AP4) receptors and [3H]AP4 binding sites in the rat brain Brain Research. 375: 204-209. PMID 3013370 DOI: 10.1016/0006-8993(86)90977-7 |
0.26 |
|
| 1988 |
Bridges RJ, Kadri MM, Monaghan DT, Nunn PB, Watkins JC, Cotman CW. Inhibition of [3H]alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid binding by the excitotoxin beta-N-oxalyl-L-alpha,beta-diaminopropionic acid. European Journal of Pharmacology. 145: 357-9. PMID 2895006 DOI: 10.1016/0014-2999(88)90442-6 |
0.25 |
|
| 2007 |
Queen SA, Kesslak JP, Bridges RJ. Regional distribution of sodium-dependent excitatory amino acid transporters in rat spinal cord. The Journal of Spinal Cord Medicine. 30: 263-71. PMID 17684893 |
0.238 |
|
| 2010 |
Balázs R, Bridges RJ, Cotman CW. Excitatory Amino Acid Transmission and Synaptic Plasticity Excitatory Amino Acid Transmission in Health and Disease. 1-51. DOI: 10.1093/acprof:oso/9780195150025.003.0011 |
0.235 |
|
| 2010 |
Balázs R, Bridges RJ, Cotman CW. Molecular Organization of Glutamate Receptors in the Postsynaptic Density Excitatory Amino Acid Transmission in Health and Disease. 1-21. DOI: 10.1093/acprof:oso/9780195150025.003.0009 |
0.223 |
|
| 1993 |
Miller S, Bridges RJ, Cotman CW. Stimulation of phosphoinositide hydrolysis by trans-(+/-)-ACPD is greatly enhanced when astrocytes are cultured in a serum-free defined medium. Brain Research. 618: 175-8. PMID 8402173 DOI: 10.1016/0006-8993(93)90443-Q |
0.211 |
|
| 2012 |
Sontheimer H, Bridges RJ. Sulfasalazine for brain cancer fits Expert Opinion On Investigational Drugs. 21: 575-578. PMID 22404218 DOI: 10.1517/13543784.2012.670634 |
0.205 |
|
| 1989 |
Cotman CW, Geddes JW, Bridges RJ, Monaghan DT. N-methyl-D-aspartate receptors and Alzheimer's disease Neurobiology of Aging. 10: 603-605. PMID 2572983 DOI: 10.1016/0197-4580(89)90144-9 |
0.197 |
|
| 2010 |
Balazs R, Bridges RJ, Cotman CW, Cotman CA. Excitatory Amino Acid Transmission in Health and Disease Excitatory Amino Acid Transmission in Health and Disease. 1-380. DOI: 10.1093/acprof:oso/9780195150025.001.0001 |
0.196 |
|
| 2016 |
Oleaga C, Bernabini C, Smith AS, Srinivasan B, Jackson M, McLamb W, Platt V, Bridges R, Cai Y, Santhanam N, Berry B, Najjar S, Akanda N, Guo X, Martin C, et al. Multi-Organ toxicity demonstration in a functional human in vitro system composed of four organs. Scientific Reports. 6: 20030. PMID 26837601 DOI: 10.1038/Srep20030 |
0.076 |
|
| 1991 |
Kirstein CL, Coopersmith R, Bridges RJ, Leon M. Glutathione levels in olfactory and non-olfactory neural structures of rats. Brain Research. 543: 341-6. PMID 1711912 DOI: 10.1016/0006-8993(91)90047-Y |
0.061 |
|
| 2003 |
Lin AY, Altiere RJ, Harris WT, Sims PJ, Ganther JM, Meyer SM, Kradjan WA, Bennett M, Crabtree BL, Goode JV, Love RC, Rospond RM, Sorenson TD, Flynn AA, Callery PS, ... ... Bridges RJ, et al. Leadership: The Nexus Between Challenge and Opportunity: Reports of the 2002–03 Academic Affairs, Professional Affairs, and Research and Graduate Affairs Committees American Journal of Pharmaceutical Education. 67: S05. DOI: 10.5688/Aj6703S05 |
0.046 |
|
| 2012 |
Cardozo-Pelaez F, Bridges RJ. Coupling biomarkers and drug action for neurodegenerative disease therapies: does the nose know?: Commentary on Sattler et al.: human nasal olfactory epithelium as a dynamic marker for CNS therapy development. Experimental Neurology. 235: 508-12. PMID 22465461 DOI: 10.1016/J.Expneurol.2012.03.006 |
0.027 |
|
| Hide low-probability matches. |